Alberta startup to develop new diagnostics for prostate cancer
EDMONTON (November 16, 2017) – A new biotechnology spinoff with roots in a GlycoNet project is planning to capitalize on the discovery of a novel cancer-specific sugar to develop new diagnostic tools and drugs for prostate cancer.
GlyCa BioSciences Inc., based in Edmonton, is founded on the intellectual property developed by Dr. Hon Leong (Western University) and his co-inventor Dr. Karla Williams (University of British Columbia), who discovered a sugar released into the blood by prostate cancer cells. This breakthrough set the foundation for the development of a diagnostic tool that uses this sugar as a biomarker to detect high-risk prostate cancer with a simple blood test.
“What’s really amazing is that we’re now starting to seriously consider that sugars generated by these aggressive cancers can be exploited for human gain,” says Dr. Leong, Chief Scientific Officer and a founder of the new company.